<DOC>
	<DOCNO>NCT00240994</DOCNO>
	<brief_summary>The purpose study evaluate safety alemtuzumab kidney transplantation part multitherapy regimen prevent kidney graft loss death avoid steroid chronic use calcineurin inhibitor pediatric renal transplant recipient 1 20 year age .</brief_summary>
	<brief_title>Safety Immunomodulatory Functions Alemtuzumab ( Campath ) Pediatric Kidney Transplantation Recipients</brief_title>
	<detailed_description>Kidney transplantation widely consider treatment choice child End Stage Renal Disease ( ESRD ) . Improvements surgical technique , donor selection , immunosuppression practice , well enhanced experience specialize pediatric transplant team , lead marked improvement patient kidney graft survival infant young child age 1 10 . However , young child infection follow transplant previously . Also , improve graft survival observe pediatric renal transplant recipient 11 17 year age . Some study indicate poor long term outcome patient kidney survival observe age group may cause noncompliance immunosuppressive medication . Therefore , protocol minimize use immunosuppressive medication retain kidney function necessary improving graft patient survival child . This study evaluate safety regimen contain alemtuzumab kidney transplantation , follow steroid avoidance calcineurin inhibitor withdrawal pediatric renal transplant recipient 1 20 year age . The accrual period schedule 18 month . The study follow-up period last 24 month . All participant enrol undergo treatment schedule : 1 . ) All participant receive intravenous alemtuzumab one day transplantation 1 day transplantation . 2 . ) Mycophenolate mofetil ( MMF ) administer orally later 2 day transplantation . 3 . ) Participants begin take oral tacrolimus twice day 1 3 day transplantation Weeks 8 12 4 . ) Sirolimus initiate . 5 . ) Sirolimus MMF take orally Month 24 . Blood collection occur baseline , 1 day transplant , Days 1 3 , Weeks 2 , 4 , 6 , 8 , 10 , Months 3 24 . Scheduled kidney ( renal ) biopsy perform transplant , Weeks 8 12 , immediately conversion sirolimus , Months 6 24 .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Between age 1 20 ( prior 21st birthday ) End Stage Renal Disease Necessity kidney transplant First kidney transplant receive living donor A living kidney donor identify No known contraindication therapy alemtuzumab Negative pregnancy test study entry Willing use approve method contraception duration study , 6 week discontinuation MMF , 12 week discontinuation sirolimus Informed consent participant , parent , guardian Current vaccination , include varicellazoster ( VZV ) vaccine , study enrollment Recipient decease donor kidney transplant Multiorgan transplant History prior organ transplantation Participant sensitize great 0 % Panel Reactive Antibody ( PRA ) within 4 week study enrollment . ( If participant receives blood transfusion status post PRA test , PRA must repeat within 1 week transplantation ) Participants human leukocyte antigen ( HLA ) identical living related donor History primary focal segment glomerulosclerosis History disorder require continuous maintenance steroid calcineurin inhibitor Active systemic infection time transplant History malignancy Infected human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) Contraindication receive tacrolimus , sirolimus , MMF , monoclonal antibody therapy Use investigational drug within 4 week study enrollment Recipient license investigational live attenuate vaccine ( ) within 2 month study enrollment Family history high cholesterol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>End stage renal disease</keyword>
	<keyword>Kidney transplantation</keyword>
	<keyword>Renal transplantation</keyword>
	<keyword>Kidney failure</keyword>
	<keyword>Pediatric renal transplant recipient</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Campath</keyword>
	<keyword>Mycophenolate mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Rapamycin</keyword>
</DOC>